ArticleCancer epidemiology2026
Assessing Concordance of Cancer Registry Data and Electronic Health Record Data in Metastatic Cancer: a Cohort Study of Patients with Colorectal Liver Metastasis in a U.S. Integrated Health System.
Article in Cancer epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Rates of metastatic cancer are increasing, but our knowledge of the accuracy of metastatic diagnoses within real world data is limited. In this brief report, to evaluate the accuracy of various data sources, we assessed concordance between cancer registry diagnoses and electronic health record (EHR) International Classification of Diseases diagnoses for the presence of colorectal liver metastases (CRLM) for patients within a single academic health care system. 1025 patients diagnosed with CRLM were evaluated. Concordance between cancer registry data and EHR data for the diagnosis of synchronous CRLM was low (k = 0.66). Additional data quality issues identified included (1) a 9 % rate of false positives in cancer registry data for the diagnosis of CRLM and (2) discordant data between the metastatic diagnosis and cancer registry stage affecting 16 % of cases. These results highlight important limitations of real world databases in the identification and study of patients with metastatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.